- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00733876
Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury Following Cardiac Surgery
August 5, 2014 updated by: AlloCure Inc.
Phase I Clinical Trial, Dose-escalating Intra-aortic Infusion of Allogeneic , Bone Marrow-derived Multipotent Stromal Cells to Prevent and Treat Post-operative Acute Kidney Injury in Patients Who Require On-pump Cardiac Surgery
The purpose of this trial is to determine if the administration of allogeneic MSCs at defined doses is safe in patients who are at high risk of developing significant Acute Kidney Injury (AKI) after undergoing on-pump cardiac surgery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Utah
-
Murray, Utah, United States, 84157
- Intermountain Medical Center
-
Salt Lake City, Utah, United States, 84124
- St Mark's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Documented ischemic coronary heart and/or valvular heart disease:Acceptable candidate for elective CABG and/or Cardiac Valve Surgery
- Patients at high risk for post-op AKI:Age 18 or older if at high risk for post-op AKI because of underlying Diabetes mellitus (type I or II), CHF, COPD Chronic Kidney Disease (CKD) stage 1-4
- Patients at high risk for post-op AKI :age > 65 or combinations
- Patent femoral artery without aortic aneurysm
- Ability to give informed consent.
Exclusion Criteria:
- Presence of ongoing local or systemic infection
- Younger than 18
- Participation in another clinical trial
- Pregnancy
- Contraindication to general anesthesia
- Prisoner
- Dialysis patient (CKD-6) or patient with CKD-5
- History of malignancy except non-melanoma skin cancer
- Occluded Groin arteries
- Uncontrolled Diabetes mellitus (HbA1c > 10, history of diabetic ketoacidosis or osmolar coma within the last three months)
- Non-healing foot ulcers.
- Clinical evidence of severe peripheral vascular disease (ABI < 0.3)
- Coronary Angiogram < 7 days before surgery
- Inadequate pre-operative time to obtain baseline kidney function data due to urgent/emergent surgery
- Unstable myocardium (evolving myocardial infarction), cardiogenic shock
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: A
|
Post-operative administration of MSC
Dose escalation protocol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Absence of MSC-specific Adverse or Serious Adverse Events
Time Frame: In hospital, monthly x 6, yearly x 3
|
In hospital, monthly x 6, yearly x 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Christof Westenfelder, MD, AlloCure Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Zhao L, Hu C, Zhang P, Jiang H, Chen J. Preconditioning strategies for improving the survival rate and paracrine ability of mesenchymal stem cells in acute kidney injury. J Cell Mol Med. 2019 Feb;23(2):720-730. doi: 10.1111/jcmm.14035. Epub 2018 Nov 28.
- Togel FE, Westenfelder C. Kidney protection and regeneration following acute injury: progress through stem cell therapy. Am J Kidney Dis. 2012 Dec;60(6):1012-22. doi: 10.1053/j.ajkd.2012.08.034. Epub 2012 Oct 2.
- Westenfelder C, Togel FE. Protective actions of administered mesenchymal stem cells in acute kidney injury: relevance to clinical trials. Kidney Int Suppl (2011). 2011 Sep;1(3):103-106. doi: 10.1038/kisup.2011.24.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2008
Primary Completion (ACTUAL)
May 1, 2010
Study Completion (ACTUAL)
October 1, 2013
Study Registration Dates
First Submitted
August 11, 2008
First Submitted That Met QC Criteria
August 11, 2008
First Posted (ESTIMATE)
August 13, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
August 6, 2014
Last Update Submitted That Met QC Criteria
August 5, 2014
Last Verified
August 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NG-IMC001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Tubular Necrosis, Acute
-
Assistance Publique - Hôpitaux de ParisTerminated
-
First Affiliated Hospital, Sun Yat-Sen UniversitySecond Affiliated Hospital of Guangzhou Medical UniversityUnknownKidney Transplantation | Acute Kidney Tubular NecrosisChina
-
First Affiliated Hospital, Sun Yat-Sen UniversitySecond Affiliated Hospital of Guangzhou Medical UniversityUnknownKidney Transplantation | Acute Kidney Tubular NecrosisChina
-
Nantes University HospitalCompletedAcute Renal Failure | Chronic Kidney Failure | Acute Kidney Tubular Necrosis
-
University of California, San FranciscoRecruitingCirrhosis | Acute Kidney Injury | Portal Hypertension | Hepatorenal Syndrome | Acute Tubule Necrosis | Prerenal FailureUnited States
-
National Institute of Diabetes and Digestive and...RecruitingKidney Failure, Chronic | Healthy Volunteers | Kidney Failure | Kidney Disease | Renal Tubular ToxicityUnited States
-
Northwestern UniversityTransplant Genomics, Inc.RecruitingAcute Rejection (AR) of Transplanted Kidney | Chronic Allograft Nephropathy (CAN) | Interstitial Fibrosis (IF) | Tubular Atrophy (TA)United States
-
Universitaire Ziekenhuizen KU LeuvenUnknown
-
University Hospital Inselspital, BerneCompletedNephrolithiasis | Acidosis, Renal Tubular | Vacuolar Proton-Translocating ATPasesSwitzerland
-
Medical University of ViennaCompletedAcidosis, Renal Tubular
Clinical Trials on Multipotent Stromal Cells
-
Guangzhou General Hospital of Guangzhou Military...First Affiliated Hospital, Sun Yat-Sen University; Guangzhou First People's... and other collaboratorsUnknownSevere Aplastic AnemiaChina
-
Guangzhou General Hospital of Guangzhou Military...UnknownParkinson's DiseaseChina
-
Guangzhou General Hospital of Guangzhou Military...UnknownSpinal Cord InjuryChina
-
Guangzhou General Hospital of Guangzhou Military...Guangzhou Municipal Twelfth People's Hospital; Guangdong Prevention and Treatment...Unknown
-
University of CambridgeCambridge University Hospitals NHS Foundation Trust; Medical Research CouncilCompleted
-
The University of Texas Health Science Center,...RecruitingTreatment-resistant Bipolar DepressionUnited States
-
Istituto Ortopedico GaleazziUnknownComplications; Implant, OrthopedicItaly
-
Emory UniversityWithdrawnBone NeoplasmsUnited States
-
Leiden University Medical CenterCompletedRejection | Graft LossNetherlands
-
Guangdong Provincial Hospital of Traditional Chinese...CompletedPsoriasis | Drug Effect | Drug Toxicity | Mesenchymal Stromal CellsChina